BioCentury | Sep 19, 2019
Translation in Brief

Public funding highlights

...drug delamanid from Otsuka Pharmaceutical Co. Ltd. (Tokyo:4578) against standard-of-care isoniazid. The study will assess delamanid's...
BioCentury | Aug 5, 2017
Regulation

Enabling efficiency in TB

...against a SOC control arm. Drugs included in the experimental arms include Sirturo, Otsuka's Deltyba delamanid...
BioCentury | Jun 16, 2016
Distillery Therapeutics

Therapeutics: An undetermined target

...Leishmaniasis Cell culture and mouse studies suggest Deltyba delamanid could help treat leishmaniasis. In vitro, Deltyba...
...Leishmania donovani promastigotes with an EC50 of 15.5 nM and in L. donovani-infected mouse macrophages, Deltyba...
...dosage and determining the L. donovani enzyme that Deltyba targets. Otsuka Pharmaceutical Co. Ltd. markets Deltyba...
BioCentury | Feb 20, 2015
Clinical News

TB Alliance begins Phase I trial of TBA-354

...multidrug-resistant TB (MDR-TB). It also said oral TBA-354 had more favorable pharmacokinetic properties than Deltyba delamanid...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...Obesity U.S. Otsuka Pharmaceutical Co. Ltd., a subsidiary of Otsuka Holdings Co. Ltd. (Tokyo:4578) Deltyba delamanid...
BioCentury | Jul 14, 2014
Clinical News

Deltyba delamanid regulatory update

...Otsuka said Japan’s Ministry of Health, Labor and Welfare (MHLW) approved Deltyba delamanid to treat pulmonary...
...plans to launch the product about 8 weeks following approval, which occurred on July 4. Deltyba...
...end of the year. Otsuka Pharmaceutical Co. Ltd ., Tokyo, Japan Product: Deltyba delamanid ( OPC-67683...
BioCentury | Jul 14, 2014
Finance

2Q Stock Wrap-Up: Large and in charge

...Ltd., a subsidiary of Otsuka Holdings Co. Ltd. (Tokyo:4578) EC grants conditional approval to Deltyba delamanid...
BioCentury | Jul 7, 2014
Top Story

Japan approves drugs for cancer, HCV, TB

...U.S. for HCV genotype 1b infection. The agency also gave the green light to Deltyba delamanid...
...from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) to treat pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults. Deltyba...
BioCentury | May 5, 2014
Clinical News

Deltyba delamanid regulatory update

...The European Commission granted conditional approval to Deltyba delamanid from Otsuka to treat pulmonary multidrug-resistant tuberculosis...
...Otsuka will launch a program that includes distribution control, medical education about the administration of Deltyba...
...the product this year. Otsuka Pharmaceutical Co. Ltd. , Tokyo, Japan Product: Deltyba delamanid ( OPC-67683...
BioCentury | May 1, 2014
Company News

EC approves Otsuka's TB drug Deltyba

...The European Commission granted conditional approval to Deltyba delamanid from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan...
...Otsuka will launch a program that includes distribution control, medical education about the administration of Deltyba...
...registry. To gain full approval, Otsuka is required to complete a Phase III trial of Deltyba...
Items per page:
1 - 10 of 29